Dermatology and Therapy最新文献

{"title":"Gut-Brain-Skin Axis: From Mechanistic Insights to Translational Applications in Neurocosmetics.","authors":"Ruohan Zhao, Huilin Xu, Yirui Zhu, Huailong Chang, Bin Liu, Zhongwang Liu","doi":"10.1007/s13555-026-01892-x","DOIUrl":"10.1007/s13555-026-01892-x","url":null,"abstract":"<p><p>The gut-brain-skin axis is a proposed integrative framework describing interactions among the gastrointestinal tract, skin, and nervous system through neural, endocrine, immune, and microbial processes. Accumulating evidence has redefined the skin as a sophisticated neuro-immune-endocrine organ rather than a passive barrier, providing the fundamental mechanistic basis for the burgeoning interdisciplinary field of neurocosmetics. However, most existing reviews have focused on the unidirectional regulation from gut to skin and from brain to skin, lacking systematic analysis of the reverse signaling from skin to nervous system and its potential for cosmetic transformation. This article addresses this gap by providing a comprehensive, mechanism-oriented integrative discussion of the gut-brain-skin axis, with a focus on the ascending skin-to-central signal pathways and their significance for neurocosmetics. This review first establishes the gut-brain axis as the core framework for barrier organ-central nervous system crosstalk, then systematically delineates the key molecular and cellular mechanisms underlying the skin-brain axis-the central pillar of neurocosmetics. This article further identifies conserved regulatory hubs and shared pathological mechanisms that underlie the comorbidity of atopic dermatitis, depression, and irritable bowel syndrome. Building on this integrated framework, this review evaluates several mechanistically grounded neurocosmetic development strategies, identifies pressing translational challenges, and proposes priority directions for future research. In summary, this article provides an evidence-based framework for understanding how the gut-brain-skin axis underpins the scientific basis of neurocosmetics and proposes a translational skincare framework that integrates overall homeostasis, stress protection, and emotional health.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"4823-4855"},"PeriodicalIF":4.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13650220/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148789416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elongated Corkscrew Hairs as a Possible Novel Trichoscopic Sign in Endothrix Tinea Capitis Affecting Adults with Immunosuppression.","authors":"Asmahane Souissi, Raquel de Melo Carvalho, Malek Ben Slimane, Mohammad Jafferany, Daniel Fernandes Melo","doi":"10.1007/s13555-026-01902-y","DOIUrl":"10.1007/s13555-026-01902-y","url":null,"abstract":"<p><strong>Introduction: </strong>Tinea capitis is a fungal infection of the scalp in which trichoscopy plays an important role by allowing early identification of characteristic hair shaft alterations before mycological confirmation.</p><p><strong>Methods: </strong>We describe two adult women who are immunosuppressed with endothrix tinea capitis caused by Trichophyton violaceum.</p><p><strong>Results: </strong>Both patients presented with diffuse scalp alopecia and scaling. Trichoscopic examination revealed unusually elongated corkscrew hairs, and fungal cultures confirmed the diagnosis.</p><p><strong>Conclusions: </strong>Elongated corkscrew hairs represent a previously unreported trichoscopic pattern in chronic endothrix tinea capitis. Awareness of this finding may facilitate earlier diagnostic suspicion and prompt targeted mycological investigation in patients who are immunosuppressed.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"5257-5262"},"PeriodicalIF":4.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13650081/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148850099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Expanding Role of GLP-1 Receptor Agonists and Dual GIP/GLP-1 Agonists in Dermatology: From Immunometabolism to Clinical Practice.","authors":"Caterina M Giorgio, Carola Romanò, Mariachiara Arisi, Mariateresa Rossi, Marina Venturini, Sara Mezzana, Laura Grigolato, Benedetta Galli, Maria M Nicoletti, Cesare Tomasi, Gaetano Licata","doi":"10.1007/s13555-026-01916-6","DOIUrl":"10.1007/s13555-026-01916-6","url":null,"abstract":"<p><p>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists (dual GIP/GLP-1 agonists) have rapidly changed the management of obesity and type 2 diabetes mellitus. Beyond their effects on weight reduction and glycemic control, these agents exert pleiotropic effects on inflammation, adipose tissue biology, endothelial function and tissue repair, properties of growing relevance to dermatology, where several chronic inflammatory diseases are closely linked to obesity, insulin resistance and systemic low-grade inflammation. Current evidence suggests potential clinical benefit in psoriasis and hidradenitis suppurativa, encouraging signals regarding wound healing and a generally favorable cutaneous safety profile, although cutaneous adverse events, including injection site reactions, hypersensitivity, alopecia and rare autoimmune eruptions, have been increasingly reported. This review summarizes the immunometabolic rationale, current clinical evidence, the dermatologic safety profile and future perspectives of GLP-1RAs and dual GIP/GLP-1 agonists in dermatology. Although available data remain heterogeneous and largely observational outside psoriasis and hidradenitis suppurativa, these therapies may represent a new class of systemic immunometabolic modulators with practical implications for inflammatory, surgical and aesthetic dermatology.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"4897-4912"},"PeriodicalIF":4.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13650102/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148954901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of the First Adalimumab Biosimilar in Chinese Children with Severe Plaque Psoriasis: The PISCES Study, a Multicenter Prospective Study.","authors":"Yirong Huang, Ting Pan, Xin Shi, Guoqiang Zhang, Fang Cheng, Songmei Geng, Heng Gu, Shanshan Li, Qingchun Diao, Xiaohua Wang, Yonghong Lu, Chao Ji, Yuzhen Li, Yuling Shi, Jun Gu, Lingling Chen","doi":"10.1007/s13555-026-01897-6","DOIUrl":"10.1007/s13555-026-01897-6","url":null,"abstract":"<p><strong>Introduction: </strong>Adalimumab, a monoclonal antibody targeting tumor necrosis factor-alpha, has been approved for the treatment of severe plaque psoriasis in children aged 4 years and older. Data on its use in the clinical management of pediatric psoriasis in China remains limited. This study is the first prospective analysis of the adalimumab biosimilar (GELELI®, the first biosimilar of adalimumab approved in China, and QLETLI® in the UK) safety and effectiveness for severe pediatric plaque psoriasis in China.</p><p><strong>Methods: </strong>Weight-based dosage was administered to 80 patients (ages 4-18 years) from multiple centers. Primary endpoints included the proportions of patients achieving PASI75 and PGA 0/1 at week 16.</p><p><strong>Results: </strong>The mean psoriasis area and severity index (PASI) score decreased from 15.31 ± 8.375 at baseline to 6.29 ± 4.208 at week 4. PASI 50/90/100 response rates were 91.1%, 49.4%, and 21.5% at week 12. At week 16, 81.0% and 68.4% of patients attained PASI75 and PGA 0/1, respectively. The incidence of adverse events was 82.5%. Adverse drug reactions accounted for 62.5%. No serious adverse events were reported.</p><p><strong>Conclusions: </strong>The biosimilar demonstrates efficacy and safety in the treatment of Chinese children with severe plaque psoriasis, consistent with clinical trial data for the originator drug.</p><p><strong>Trial registration: </strong>Clinicaltrials.gov: NCT05803187.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"5161-5173"},"PeriodicalIF":4.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13650105/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148900251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Effectiveness and Safety of Bimekizumab for Moderate-to-Severe Hidradenitis Suppurativa: A Multicenter Retrospective Study from the Italian Landscape HS (IL-HS).","authors":"Mario Valenti, Ruggero Cascio Ingurgio, Luciano Ibba, Edoardo Cammarata, Raffaele D Caposiena Caro, Andrea Carugno, Martina Dragotto, Claudio Marasca, Piergiorgio Malagoli, Fabrizio Martora, Angelo V Marzano, Matteo Megna, Santo R Mercuri, Francesco Messina, Alessandra Michelucci, Chiara Moltrasio, Giovanni Paolino, Federica Repetto, Simone Ribero, Luigi Rossiello, Emanuele Trovato, Nicola Zerbinati, Antonio Costanzo, Alessandra Narcisi, Valentina Dini","doi":"10.1007/s13555-026-01891-y","DOIUrl":"10.1007/s13555-026-01891-y","url":null,"abstract":"<p><strong>Introduction: </strong>Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by painful nodules, abscesses, draining tunnels and substantial impairment in quality of life. Bimekizumab, a monoclonal antibody that selectively inhibits interleukin-17A and interleukin-17F, was recently approved in Italy for the treatment of moderate-to-severe HS. However, real-world evidence remains limited.</p><p><strong>Methods: </strong>This was a retrospective multicenter study of patients with HS treated with bimekizumab across Italian dermatology referral centers. Effectiveness was assessed at weeks 4, 16 and 24 using the following measurement tools and scales: Hidradenitis Suppurativa Clinical Response (HiSCR), HiSCR75, HiSCR90, HiSCR100 (at least 75%, 90% and 100% reductions in AN count, respectively, plus HiSCR criteria), the International Hidradenitis Suppurativa Severity Score System 55% reduction (IHS4-55), International Hidradenitis Suppurativa Severity Score System (IHS4), draining tunnel count, abscess and inflammatory nodule (AN) count, AN50 (at least 50% reduction in AN), pain numerical rating scale (NRS-pain), NRS50 (as at least a 50% reduction in NRS-pain compared with baseline) and Dermatology Life Quality Index (DLQI). Safety outcomes included adverse events, rescue therapies and concomitant treatments.</p><p><strong>Results: </strong>A total of 100 patients were included in the study among whom 56% were male and the mean age was 37.3 years. Median body mass index was 26.8 kg/m², 75% had Hurley stage III disease and 80% had prior biologic exposure. HiSCR was achieved by 36 of 100 (36.0%) patients at week 4, 60 of 100 (60.0%) patients at week 16 and 41 of 53 (77.4%) patients at week 24. HiSCR75 was achieved by 24 of 100 (24.0%) patients, 48 of 100 (48.0%) patients and 35 of 53 (66.0%) patients at weeks 4, 16 and 24, respectively. Median IHS4 decreased from 18 at baseline to 7 at week 24; median draining tunnel count decreased significantly from baseline at all visits, median AN count decreased from 3.5 to 1, median NRS-pain decreased from 8 to 3, and median DLQI decreased from 19.5 to 7. IHS4-55 was achieved by 54.7% of evaluable patients at week 24. Flare rates remained below 10% throughout follow-up. Any adverse event was reported in 22 patients (22.0%).</p><p><strong>Conclusion: </strong>In this multicenter Italian real-world cohort, bimekizumab was associated with early clinical improvement and meaningful reductions in disease activity, pain and quality-of-life burden; week-24 estimates should be interpreted in light of administrative censoring.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"5069-5084"},"PeriodicalIF":4.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13650090/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148849843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Affecting High-Impact Sites: Pooled Results Across the ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 and 2 Phase 3 Trials.","authors":"Mark G Lebwohl, Melinda Gooderham, Richard B Warren, Lawrence F Eichenfield, Jessica H Rubens, Tracy Cardillo, Christopher Russo, Cynthia M C DeKlotz, Megan Miller-Kassamali, Luis Anaya Velarde, Ming-Chun Hsu, Shu Li, Ya-Wen Yang, Sarah Ofori, Robert Bissonnette, Jennifer Soung, Adelaide A Hebert, Linda Stein Gold","doi":"10.1007/s13555-026-01885-w","DOIUrl":"10.1007/s13555-026-01885-w","url":null,"abstract":"<p><strong>Introduction: </strong>Icotrokinra, a first-in-class targeted oral peptide, precisely blocks the interleukin (IL)-23 receptor and inhibits IL-23 pathway signaling. In phase 3 studies (ICONIC-LEAD, ICONIC-TOTAL, ICONIC-ADVANCE 1 and 2), icotrokinra provided superior skin clearance versus placebo and deucravacitinib in adults and adolescents with moderate-to-severe psoriasis and psoriasis affecting high-impact sites. This analysis evaluates icotrokinra safety through 1 year using pooled data from these four studies.</p><p><strong>Methods: </strong>Icotrokinra-randomized participants received 200-mg pills once daily, and placebo-randomized participants crossed over to icotrokinra at week 16; participants randomized to deucravacitinib 6 mg (ICONIC-ADVANCE 1 and 2 only) switched to icotrokinra at week 24. Pooled safety data are summarized for the placebo-controlled period (week 0-16, all studies), active-controlled period (week 0-24, ICONIC-ADVANCE 1 and 2), and through week 52 (all studies).</p><p><strong>Results: </strong>During the placebo-controlled period across all studies, 568 participants received placebo and 1296 received icotrokinra. From week 0 to 24 in the ICONIC-ADVANCE studies, 632 participants received icotrokinra and 634 received deucravacitinib. Through week 52, 2400 icotrokinra-treated participants contributed 1840 participant-years [PY] of follow-up. Through week 16, in the icotrokinra and placebo groups, respectively, exposure-adjusted incidence rates/100 PY of adverse events (AEs; 232 and 269), serious AEs (5.2 and 6.6), infections (91 and 104), and AEs leading to discontinuation (6.6 and 10.0) were comparable between groups. Through week 24, in the ICONIC-ADVANCE studies, rates/100 PY with icotrokinra versus deucravacitinib were as follows: AEs, 204 vs 265; serious AEs, 6.4 vs 7.2; infections, 81 vs 119; AEs leading to discontinuation, 5.7 vs 6.8. Through week 52, event rates/100 PY in icotrokinra-treated participants were as follows: AEs, 167; serious AEs, 4.6; infections, 76; AEs leading to discontinuation, 3.0.</p><p><strong>Conclusion: </strong>In this analysis of 2400 icotrokinra-treated participants with psoriasis followed through 1 year, icotrokinra demonstrated favorable safety; event rates through week 16 were similar to placebo and remained consistent through week 52.</p><p><strong>Clinicaltrials: </strong>GOV: NCT06095115, NCT06095102, NCT06143878, NCT06220604. Infographic available for this article. INFOGRAPHIC.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"5049-5068"},"PeriodicalIF":4.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13650227/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148849814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dermatologists' Perspectives and Real-World Assessment of Alopecia Areata Severity, Burden, and Healthcare Resource Utilization in Adults in the United Arab Emirates.","authors":"Fatima Albreiki, Ayman Ahmed Essa Al Naeem, Muna Mohamed Al Safi, Ahmed Ameen, Pervaz Ahmad Mohammad, Mostafa Zayed, Haytham Mohamed Ahmed, Diala Hamza, Zeina Azrak, Samantha K Kurosky, Gerardo A Encinas, Peter Anderson, Ashley S Cha-Silva, Shailja Vaghela, Juliana Machado Canosa","doi":"10.1007/s13555-026-01874-z","DOIUrl":"10.1007/s13555-026-01874-z","url":null,"abstract":"<p><strong>Introduction: </strong>Alopecia areata (AA), an autoimmune disease, causes hair loss on the scalp, face, and body, with approximately 2% prevalence in the Middle East. AA is associated with significant impacts to patient quality of life (QoL). This study evaluated dermatologist perceptions and experiences treating AA in the United Arab Emirates (UAE) as new targeted treatments became available, as well as patient disease burden and unmet treatment needs.</p><p><strong>Methods: </strong>Data were from the Adelphi Real World AA Disease Specific Programme™ (September 2022-March 2023). Dermatologists rated statements on diagnosing and managing AA by agreeing or disagreeing and provided clinical and treatment information on one patient each with mild, moderate, and severe/very severe AA. Some of these patients completed questionnaires (Skindex-16, Hospital Anxiety and Depression Scale, and Work Productivity and Activity Impairment-AA [WPAI-AA]). Results stratification included by percent scalp hair loss (SHL).</p><p><strong>Results: </strong>Analyses included 53 dermatologists and 144 patients. Most dermatologists reported severe AA management was difficult because of lack of effective treatments. A median SHL of 61.0% was reported as typical of severe AA. The most frequently reported factor informing disease severity was impact of AA on QoL. Overall, 32.6% of patients had physician-assessed severe/very severe AA. Anxiety and depression rates were consistent across SHL categories. Patients with ≥ 21% SHL reported significantly higher impact of AA on QoL (mean Skindex-16 scores). Patients with ≥ 50% SHL reported higher presenteeism on the WPAI-AA. Almost all patients were currently receiving their first AA treatment; patients with ≥ 50% SHL received different treatments than those with < 50% SHL. Healthcare resource utilization and costs were lower among patients with < 50% SHL.</p><p><strong>Conclusions: </strong>In the UAE, impacts on patient QoL and the economic burden associated with AA are important factors to consider and may aid dermatologists in setting treatment goals and selecting therapies as newer targeted therapies emerge.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"4961-4974"},"PeriodicalIF":4.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13650207/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148757804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Efficacy of Intradermal Stromal Vascular Fraction Injection Versus Saline Injection in the Treatment of Atrophic Acne Scar: A 10-Week, Prospective, Randomized, Split-Face, Single-Blind Controlled Trial.","authors":"Joong Heon Suh, Ji-Young Kim, Ji Young Yoon, Jun Hyo Lee, Dong Hyo Kim, Ungsik Jin, Dae Hun Suh","doi":"10.1007/s13555-025-01617-6","DOIUrl":"10.1007/s13555-025-01617-6","url":null,"abstract":"<p><strong>Introduction: </strong>Management of atrophic acne scars remains challenging, and conventional treatments often yield suboptimal or inconsistent outcomes. Stromal vascular fraction (SVF), a cell-rich fraction derived from adipose tissue, has recently gained attention as a promising regenerative therapy. Several previous studies have reported benefits of SVF when combined with other treatment modalities; however, its stand-alone efficacy for atrophic acne scars has not been clearly investigated. In addition, molecular evidence supporting the regenerative effects of SVF in acne scar treatment remains limited.</p><p><strong>Methods: </strong>This randomized, evaluator-blinded, split-face clinical trial was conducted in 14 patients with bilateral facial atrophic acne scars. One side was treated with intradermal SVF injection, while the contralateral side received normal saline (NS). Clinical outcomes were assessed using scar counts, Évaluation Clinique des Cicatrices d'Acne (ECCA) scores, Scar Global Assessment (SGA) scores, and standardized photography at baseline, 5 weeks, and 10 weeks. Skin biopsies were analyzed via immunohistochemistry for markers of epidermal regeneration (cytokeratin 14, cytokeratin 15, p63, integrin β1) and dermal remodeling (collagen I, elastin, vimentin).</p><p><strong>Results: </strong>At 10 weeks after initial treatment, the SVF-treated side showed a significantly greater reduction in total scar count compared to the NS-treated side (56.4% vs. 13.2%, p < 0.001). Scar subtype analysis revealed that all scar types (ice pick, boxcar, and rolling) responded more favorably to SVF treatment, with large effect sizes (Cohen's d > 0.99). ECCA and SGA scores were also significantly decreased on the SVF-treated side. Immunohistochemical analysis revealed marked upregulation of epidermal progenitor markers and increased deposition of collagen I, elastin, and vimentin in the SVF-treated tissue.</p><p><strong>Conclusion: </strong>We clinically demonstrated that SVF injection improves atrophic acne scars and simultaneously revealed its regenerative mechanisms involving epidermal and dermal remodeling. This supports the use of SVF as an evidence-based treatment modality for atrophic acne scars.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier, NCT07094958.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"4341-4354"},"PeriodicalIF":4.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13558499/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145780415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Modified Delphi Consensus Recommendations for the Management of Psoriasis in Asia-Pacific.","authors":"Yoo Sang Baek, Siew Eng Choon, Peter Anthony Foley, Tsen Fang Tsai, Jianzhong Zhang, Yukie Yamaguchi","doi":"10.1007/s13555-026-01834-7","DOIUrl":"10.1007/s13555-026-01834-7","url":null,"abstract":"<p><strong>Introduction: </strong>Psoriasis imposes a substantial clinical and quality-of-life burden across the Asia-Pacific (APAC) region. Despite advances in systemic therapies, variability in disease severity classification, assessment tools, and treatment escalation criteria continues to contribute to undertreatment and delayed access to effective care.</p><p><strong>Methods: </strong>A modified Delphi panel was conducted to develop APAC-contextualised consensus recommendations for psoriasis management. Statements were generated from a literature review and refined through Steering Committee interviews and review. The steering committee (n = 6) and Delphi panellists (n = 12) was comprised of dermatology experts from six APAC markets (Australia, China, Japan, South Korea, Malaysia, Taiwan). Consensus was generated through two structured online voting rounds involving all panellists, followed by a moderated consensus meeting, involving only the steering committee, to deliberate on any remaining non-consensus items. Consensus was defined a priori as ≥ 75% agreement among panellists.</p><p><strong>Results: </strong>In rounds 1 and 2, 92/130 (71%) and 17/24 (71%) statements achieved consensus, respectively. Eight statements were discussed during the steering committee meeting, during which consensus was reached on all eight. In total, 121 statements achieved formal consensus, which includes an additional 4 non-consensus statements from round 1 that were retained in the final recommendations based on steering committee determination of clinical relevance. Recommendations focused on severity classification and assessment thresholds, treatment goals and response criteria, and systemic therapy eligibility and escalation.</p><p><strong>Conclusion: </strong>These Delphi-derived recommendations provide a practical, patient-centred framework to standardise psoriasis assessment and guide timely treatment escalation in APAC. Adoption may reduce variability in care, support equitable access to appropriate systemic therapies, and improve outcomes across diverse APAC health systems.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"4355-4374"},"PeriodicalIF":4.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13558483/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148367466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Efficacy of a 12% Pure Vitamin C Serum Across All Skin Phototypes: An Integrated In Vitro-In Vivo Evaluation.","authors":"Flávia Alvim Sant'Anna Addor, James Odeimi, Gisele Gargantini Rezze, Erika Fernandes, Mariana Feiges, Diala Haykal, Andrea Belén Rey","doi":"10.1007/s13555-026-01862-3","DOIUrl":"10.1007/s13555-026-01862-3","url":null,"abstract":"<p><strong>Introduction: </strong>Skin aging is associated with loss of collagen network qualitative and quantitative integrity, which are crucial for skin structure and function. Topical application of pure vitamin C (L-ascorbic acid) may alleviate signs of skin aging (e.g., wrinkles, lack of firmness). The objectives of this open-label, monocentric study were to determine whether topical treatment with a dermocosmetic serum containing a high concentration (12%) of pure vitamin C (PVC12 serum) could increase epidermal thickness and positively influence collagen fiber synthesis and organization, thus alleviating visible signs of skin aging.</p><p><strong>Methods: </strong>This study investigated the efficacy and tolerability of PVC12 serum over 3 months compared with baseline. Healthy participants aged ≥18 years with any skin phototype received twice-daily treatment with the PVC12 serum. Evaluations included reflectance confocal microscopy measures and instrumental measures of skin firmness and elasticity, as well as clinical scoring of multiple skin aging signs.</p><p><strong>Results: </strong>The study included 49 women (skin phototypes I-VI). After 84 days of continuous use of PVC12 serum, epidermal thickness was significantly increased by 16.4% compared with baseline. More than half of the participants showed improvements in total collagen score and cross-linked collagen fibers. A significant decrease in coarse and curled collagen fibers was also observed. There was significant improvement in skin firmness and elasticity throughout the study. At the end of treatment, there were significant and clinically relevant improvements in various parameters (e.g., radiance, skin oiliness, pores). The treatment was well tolerated, with no occurrence of treatment-related adverse events.</p><p><strong>Conclusion: </strong>PVC12 serum may exert beneficial effects on skin of all phototypes, including improved skin thickness, collagen fiber synthesis and quality, skin firmness and elasticity, and other parameters. This evidence supports the effectiveness and tolerability of pure vitamin C in the prevention and correction of skin aging signs over time.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"4551-4564"},"PeriodicalIF":4.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13558500/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148590857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}